Top 5 International Companies To Watch For 2014

Sales at America's automakers have been going great guns these past few quarters, and you'd think that would be great news for the companies that make parts for all these shiny new autos. In some cases, you'd be right to think that. But in at least one case -- the case of Johnson Controls (NYSE: JCI  ) stock -- you'd be very, very wrong.

Shares of auto-parts makers such as Lear (NYSE: LEA  ) and Magna International (NYSE: MGA  ) have rocketed this past year, outperforming the S&P 500 with 46% and 56% returns, respectively. Yet Johnson Controls stock has lagged the market average by more than five points. Why?

Three reasons.

Johnson Controls stock is worse than average
Turns out that when you stack up Johnson Controls stock against its two smaller rivals, there's precious little to recommend it. Johnson Controls' P/E ratio of 27.8 is no bargain. It's more than twice the cost of a share of Magna (which costs 10.5 times earnings), and nearly six times the cost of Lear, which sells for only 4.7 times earnings.

Top 10 Semiconductor Companies To Buy For 2015: Supernus Pharmaceuticals Inc (SUPN)

Supernus Pharmaceuticals, Inc. (Supernus), incorporated on March 30, 2005, is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Supernus is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder (ADHD). Supernus�� two epilepsy product candidates are SPN-538 and Epliga. Epliga is in Phase III clinical trials. Supernus ADHD product candidates include SPN-810 (molindone hydrochloride), a treatment for impulsive aggression in patients with ADHD, and SPN-812, a non-stimulant treatment for ADHD. Both of these programs are in Phase II. In addition to these four products candidates, Supernus has several additional product candidates in various stages of development, including SPN-809. Its wholly owned subsidiary includes TCD Royalty Sub LLC.

Supernus�� Late-Stage Neurology Portfolio

SPN-538 is an oral once-daily extended release topiramate product for the treatment of epilepsy. Topiramate is marketed by Johnson & Johnson under the brand name Topamax and is available in a generic form. As of December 31, 2009, Topiramate was available only in immediate release form and is indicated for monotherapy and adjunctive therapy of epilepsy and for the treatment of migraine. It works by enhancing the inhibitory effect of the Gamma-Aminobutyric Acid (GABA) neurotransmitter that regulates neuronal excitability throughout the nervous system, blocking the excitatory effect of the glutamate neurotransmitter, blocking the sodium channel and inhibiting the carbonic anhydrase enzyme.

Epliga is an oral once-daily extended release formulation of oxcarbazepine. As of December 31, 2009, Epliga was in Phase III trials. Oxcarbazepine is marketed by Novartis under the brand name Trileptal and is available in a generic form. Trileptal is indicated for monotherap! y and adjunctive therapy of epilepsy. Oxcarbazepine is an active voltage-dependent sodium channel blocker.

Supernus�� Psychiatry Portfolio

SPN-810 (molindone hydrochloride) is a treatment for impulsive aggression in patients with ADHD. As of December 31, 2009, it was in Phase II. SPN-810 is based on molindone hydrochloride. As of December 31, 2009, the Company had completed four clinical trials for SPN-810, including a Phase IIa trial, in which it tested the safety and tolerability of immediate release molindone hydrochloride in children with ADHD who suffer from serious persistent conduct problems. This open-label, dose-ranging trial randomized 78 children, 6-12 years of age, into one of four treatment groups, which were given four different doses of immediate release molindone hydrochloride, between 10 milligram and 40 milligram per day, depending on weight, three times a day over a six-week treatment period, after 2-5 weeks of titration. SPN-810 was well tolerated in the trial with no clinically meaningful changes in standard hematology, clinical chemistry values, vital signs or electrocardiogram results. SPN-810 also showed improvements on the primary and secondary outcome measures, such as conduct problem and ADHD scales, across all four treatment groups. SPN-812 is a non-stimulant treatment for ADHD. As of December 31, 2009, SPN-812 was in Phase II. SPN-812 is a selective norepinephrine reuptake inhibitor.

Supernus�� Technology Platforms

The Company has a long track record of developing products by applying technologies to known drugs to improve existing therapies and to enable the treatment of new indications. Supernus�� main technology platforms include: Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The Company�� technologies have been used in the approved and marketed products, including Carbatrol (carbamazepine), Equetro (carbamazepine), Adderall XR (mixe! d ampheta! mine salts), Sanctura XR (trospium chloride), Oracea (doxycycline) and Intuniv (guanfacine).

Advisors' Opinion:

• [By Sara Sjolin]

  Shares of Supernus Pharmaceuticals (SUPN) �could also be active, after the company jumped 20% after-hours on Monday after a drug on which the firm collaborated received Food and Drug Administration approval.

Top 5 International Companies To Watch For 2014: AutoCanada Inc (ACQ)

AutoCanada Inc. (AutoCanada) is a multi-location automobile dealership groups. As of December 31, 2011, the Company operated 24 franchised dealerships in British Columbia, Alberta, Manitoba, Ontario, New Brunswick and Nova Scotia. During the year ended December 31, 2011, its dealerships sold approximately 28,000 vehicles and processed approximately 300,000 service and collision repair orders in its 333 service bays. As of December 31, 2011, it was authorized to sell through its dealerships the vehicle brands, which include Chrysler, Dodge, Jeep, Ram, Fiat, Hyundai, Nissan, Infiniti, Volkswagen, Mitsubishi and Subaru. In addition, it sells a range of used vehicles. In November 2011, the Company acquired assets of two dealerships. In January 2013, the Company purchased the assets of a Volkswagen dealership known as People's Automotive Ltd. Advisors' Opinion:

• [By Greg Quinn]

  AutoCanada Inc. (ACQ), the country�� largest publicly traded chain of car dealerships, is using sales of trucks to Alberta oil workers to fund higher dividends and buy out competitors.

Top 5 International Companies To Watch For 2014: Sprott Physical Gold Trust (PHYS)

Sprott Physical Gold Trust (the Trust) is a closed-end mutual fund trust. The Trust was created to invest and hold substantially all of its assets in physical gold bullion. The Trust seeks to provide an exchange-traded investment alternative for investors interested in holding physical gold bullion. The Trust invests primarily in long-term holdings of unencumbered, fully allocated, physical gold bullion and does not speculate with regard to short-term changes in gold prices. Sprott Asset Management LP (the Manager) is the manager and RBC Dexia Investor Services Trust (RBC Dexia), a trust company, is the trustee of the Trust.

The Trust employs two custodians. The Royal Canadian Mint (Mint) acts as custodian for the Trust's physical gold bullion, pursuant to a precious metals storage agreement between the Manager, for and on behalf of the Trust, and the Mint, to which it refers as the precious metals storage agreement. RBC Dexia acts as custodian of the Trust's assets other than physical gold bullion pursuant to the trust agreement. As of December 31, 2010, the Trust held 90% of its total net assets in physical gold bullion in London Good Delivery bar form. The Trust does not invest in gold certificates or other financial instruments that represent gold or that may be exchanged for gold.

In making investments on behalf of the Trust, the Manager is subject to certain investment and operating restrictions, to which the Trust refers to as the Investment and Operating Restrictions. The Investment and Operating Restrictions provide that the Trust will invest in and hold a minimum of 90% of the total net assets of the Trust in physical gold bullion in London Good Delivery bar form and hold no more than 10% of the total net assets of the Trust, at the discretion of the Manager, in physical gold bullion (in London Good Delivery bar form or otherwise), gold coins, debt obligations of or guaranteed by the Government of Canada or a province of Canada or by the Government of the United St! ates or a state thereof.

The Trust will invest in short-term commercial paper obligations of a corporation or other person whose short-term commercial paper is rated R-1 (or its equivalent, or higher) by Dominion Bond Rating Service Limited or its successors, or assigns or F1 (or its equivalent, or higher) by Fitch Ratings or its successors, or assigns or A-1 (or its equivalent, or higher) by Standard & Poor's or its successors, or assigns or P-1 (or its equivalent, or higher) by Moody's Investor Service or its successors, or assigns, interest-bearing accounts and short-term certificates of deposit issued or guaranteed by a Canadian chartered bank or trust company, money market mutual funds, short-term government debt or short-term investment grade corporate debt, or other short-term debt obligations approved by the Manager from time to time. The Trust will not purchase, sell or hold derivatives.

Advisors' Opinion:

• [By Boris Mikanikrezai]

  As India and China are the largest buyers of gold, physical demand (PHYS) out of Asia has been moderated in the recent weeks for different reasons.

• [By Daniel Gibbs]

  Gold trusts and ETFs
  One of the easiest ways to profit off of a rising gold price is to buy shares in one of the various exchange-traded gold trusts. These are essentially closed-end funds that own physical gold bullion located in a vault. Each share of the trust represents a fractional ownership share of the physical bullion in the vault. Thus, these trusts could be an easy way to purchase gold exposure directly on an exchange. One example of a trust like this is the�Sprott Physical Gold Trust (NYSEMKT: PHYS  ) .

Top 5 International Companies To Watch For 2014: Guggenheim Multi-Asset Income ETF (CVY)

The Guggenheim Multi-Asset Income ETF (the Fund), formerly Claymore/Zacks Multi-Asset Income Index ETF, seeks investment results that correspond generally to the performance of an equity index called the Zacks Multi-Asset Income Index (the Index). The Index consists of approximately 125 to 150 securities selected, based on investment and other criteria, from a universe of domestic and international companies. The universe of securities within the Index includes United States-listed common stocks, American depositary receipts (ADRs) paying dividends, real estate investment trusts, master limited partnerships, closed-end funds and traditional preferred stocks. The companies in the universe are selected using a methodology developed by the index provider, Zacks Investment Research, Inc. The Fund, using a passive or indexing investment approach, seeks to replicate the performance of the Index. The Fund�� investment advisor is Claymore Advisors, LLC. Advisors' Opinion:

• [By Genia Turanova]

  Moreover, investors can do one-stop shopping for most income classes through a single ETF as well. One interesting choice here is Guggenheim Multi-Asset Income (CVY).